Overview
NICE is unable to make a recommendation on tagraxofusp (Elzonris) for treating blastic plasmacytoid dendritic cell neoplasm. This is because Stemline Therapeutics did not provide an evidence submission.
Last reviewed: 30 March 2022
Next review: We will review this decision if the company decides to make a submission.